Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy
Adam S. Darwich(KTH Royal Institute of Technology), Amin Rostami‐Hodjegan(Manchester Academic Health Science Centre), Thomas M. Polasek(Royal Adelaide Hospital), Kayode Ogungbenro(University of Manchester), Birgit Eiermann(Inera (Sweden)), Youssef Daali(University of Geneva), Andrew J. McLachlan(The University of Sydney), Jean‐Luc Reny(University Hospital of Geneva), Lawrence J. Lesko(University of Florida), Daniel F. B. Wright(University of Otago), Brahim Achour(University of Manchester), Jeffrey K Aronson(University of Oxford), Jack Cook(Pfizer (United States))
The Annual Review of Pharmacology and Toxicology
October 9, 2020
Cited by 179
Related Papers
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
|Journal of Clinical Epidemiology|2012|1.2k
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis
|BMJ Open|2016|527
Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies
|Thrombosis and Haemostasis|2014|467